Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
113M
-
Shares change
-
+7.77M
-
Total reported value, excl. options
-
$1.6B
-
Value change
-
+$96.1M
-
Put/Call ratio
-
0.56
-
Number of buys
-
65
-
Number of sells
-
-53
-
Price
-
$14.30
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q4 2021
163 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q4 2021.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113M shares
of 293M outstanding shares and own 38.41% of the company stock.
Largest 10 shareholders include Capital World Investors (22.1M shares), Allianz Asset Management GmbH (11.2M shares), BAKER BROS. ADVISORS LP (10.5M shares), SB Management Ltd (9.82M shares), Capital International Investors (8.13M shares), DCVC Bio GP, LLC (7.31M shares), ORBIMED ADVISORS LLC (4.18M shares), HARVARD MANAGEMENT CO INC (4.11M shares), GUARDIAN CAPITAL ADVISORS LP (3.84M shares), and Founders Fund VII Management, LLC (3.77M shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.